Ketolide treatment of Haemophilus influenzae experimental pneumonia.
The MICs of HMR 3004 and HMR 3647 at which 90% of beta-lactamase-producing Haemophilus influenzae isolates were inhibited were 4 and 2 micrograms/ml, respectively. Both HMR 3004 and HMR 3647 were active against beta-lactamase-producing H. influenzae in a murine model of experimental pneumonia. As assessed by pulmonary clearance of H. influenzae, HMR 3004 was more effective (P < 0.05) than was azithromycin, ciprofloxacin, clarithromycin, erythromycin A, pristinamycin, or HMR 3647 in this model.
Division of Infectious Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA.
K E
KE
Piper
M S
MS
Rouse
J M
JM
Steckelberg
W R
WR
Wilson
R
R
Patel
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004352:Drug Resistance, Microbial; D006192:Haemophilus Infections / Q000188:drug therapy* / Q000382:microbiology; D006193:Haemophilus influenzae / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification; D006801:Humans; D048628:Ketolides; D018942:Macrolides; D051379:Mice; D008810:Mice, Inbred C57BL; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C105420:RU 64004; D001618:beta-Lactamases; C106791:telithromycin